Amylyx Announces Support from a ALS Finding a Cure Foundation and a Cure …

November 17, 2015 - als

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals now announced it has perceived $600,000 from the
ALS Finding a Cure Foundation and a Cure Alzheimer’s Fund to support
IND-enabling studies for a company’s lead candidate, AMX0035. The
Company has also lifted new private financier funding, bringing a total
lifted to $1.9 million. AMX0035 has exhibited certain preclinical
formula in restraint neuroinflammation and haughtiness dungeon genocide and is
positioned to enter clinical trials in amyotrophic parallel sclerosis
(ALS) in 2016.

“The ALS Finding a Cure Foundation is committed to posterior multiple
avenues toward a heal for ALS,” pronounced Merit Cudkowicz, MD, the
Foundation’s arch medical officer, Professor of Neurology during Harvard,
and Chief of Neurology during Massachusetts General Hospital. “AMX0035 has
shown guarantee in preclinical models. This extend will safeguard studies
indispensable to start clinical trials.”

ALS and other neurodegenerative diseases such as Alzheimer’s are
characterized by haughtiness dungeon genocide and inflammation. Together these
processes form a poisonous cycle that is a pivotal motorist of progressive
neurological decline. AMX0035 is an oral, exclusive mixed of two
famous compounds that is designed to mangle this cycle and forestall the
serve course of neurodegenerative disease. AMX0035’s potent
healing ability has been reliable in mixed models of ALS and
Alzheimer’s as good as models of dungeon genocide and inflammation.

“Across all neurodegenerative diseases from Alzheimer’s to ALS, one of
a vital sources of neuronal dungeon genocide is inflammation and oxidative
damage,” pronounced Rudy Tanzi, PhD, Professor of Neurology during Harvard Medical
School, Director of a Genetics and Aging Unit during Massachusetts General
Hospital, and Chairman of Amylyx’s Scientific Advisory Board. “If we can
forestall neuroinflammation, there is an glorious possibility that we will
significantly correct or postpone conflict of clinical symptoms across
many common neurological disorders.”

In further to Professor Tanzi, Amylyx has built a clever group of
attention and educational leaders, including Dr. George Milne, former
President of Central Research during Pfizer and Radius Venture Partner, and
Stephen D. Chubb, prior CEO of 3 publicly-traded biotechnology
companies and now Special Limited Partner during Catalyst Health

“We are respected by a support from ALS Finding a Cure, a Cure
Alzheimer’s Fund, and a investors,” pronounced Joshua Cohen, Co-Founder and
CEO of Amylyx. “We are vehement to work toward a suggestive therapy for
patients pang from this harmful illness and anticipate
rising an initial clinical hearing in ALS in 2016.”

About ALS

Amyotrophic parallel sclerosis, ALS, is a many prevalent, adult-onset
on-going engine neuron disease, inspiring approximately 30,000 people
in a US and an estimated 450,000 people worldwide. ALS causes the
on-going lapse of engine neurons, ensuing in rapidly
surpassing flesh debility and atrophy that eventually leads to partial
or sum paralysis; on normal a illness is deadly within usually four
years. There is usually one medicine authorized privately for treating
ALS, riluzole, and it usually extends presence by about 10 percent.

About Amylyx Pharmaceuticals

Amylyx is building a novel healing for Amyotrophic Lateral
Sclerosis (ALS) and other neurodegenerative diseases that targets the
neuroinflammation and haughtiness dungeon genocide that impersonate these
disorders. The company’s therapeutic, AMX0035, is a proprietary
mixed of existent compounds that Amylyx has shown have synergistic
effects in preventing dungeon genocide and neurotoxic inflammation in multiple
preclinical models. AMX0035 is approaching to enter clinical trials in ALS
patients in 2016. Learn some-more at:

Forward Looking Statements

Some statements in this press recover are not chronological contribution and
consecrate “forward-looking statements” as tangible in a Private
Securities Litigation Reform Act of 1995 that are formed on current
expectations of Amylyx management. Forward-looking statements are
theme to risks and uncertainties that could means tangible future
formula to differ materially from those voiced or pragmatic by such
statements. The reader is cautioned not to rest on these forward-looking
statements. Amylyx does not commence to refurbish forward-looking
statements to simulate a change in a views, events or circumstances
that start after a date of this release.

source ⦿

More als ...

› tags: als /